XIAP and colorectal carcinoma: By using a tissue microarray technology, immunoexpression of cIAP1, cIAP2, XIAP, Survivin and their antagonist SMAC/Diablo were evaluated in the treatment of naive colorectal carcinoma and expression levels were correlated with the levels of apoptosis, cellular proliferation and patient’s prognosis [96].